Hui-Lan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hui-Lan Wang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Hong Xin
Department of Obstetrics & Gynecology, the Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
2 shared publicationsEdward Younglai
Department of Obstetrics & Gynecology, Reproductive Biology Division, McMaster University, Health Sciences Centre, Hamilton, Ontario, Canada
1 shared publicationJing Jiang
Department of Obstetrics & Gynecology, the Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
1 shared publicationShuhan Sun
Department of Medical Genetics and Institute of Biophysics, Second Military Medical University, Shanghai, China
1 shared publicationShupeng Liu
Department of Medical Genetics and Institute of Biophysics, Second Military Medical University, Shanghai, China
1 shared publicationYanjing Wu
Department of Obstetrics & Gynecology, the Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
1 shared publication
Latest Publications
- Retracted
Retracted: Up‐regulation of microRNA‐145 promotes differentiation by repressing OCT4 in human endometrial adenocarcinoma cells
BACKGROUND: MicroRNA‐145 (miR‐145) has been reported to be a tumor‐suppressing agent in several studies. It can repress pluripotency and control human embryonic stem cell differentiation by regulating the core pluripotency factor OCT4. However, it is not known whether miR‐145 can play a role in inducing tumor cell differentiation and repressing growth of tumors. METHODS: Ishikawa cells, the established human endometrial cancer cells, were treated with miR‐145 mimics, inhibitor, or small interfering RNA OCT4. miR‐145 levels were assayed using TaqMan microRNA assays, and the messenger RNA levels of OCT4 and the differentiation marker glycodelin were measured using real‐time polymerase chain reaction. The protein levels of OCT4 and glycodelin were characterized via flow cytometry, western blotting, and immunohistochemistry. In vivo activity was measured in a xenograft mouse model. RESULTS: Up‐regulating miR‐145 reduced the expression of OCT4 and induced the differentiation of Ishikawa cells to closely resemble normal endometrial epithelium both in vitro and in vivo. miR‐145 successfully inhibited tumor growth. We also found that in patients with endometrial carcinoma, miR‐145 and OCT4 were expressed in tissues, and there was a relationship between miR‐145, OCT4, and the degree of tumor cell differentiation. CONCLUSIONS: Our results strongly suggested that miR‐145 is a tumor cell differentiation‐inducing agent in endometrial carcinoma, and that miR‐145 or OCT4 may be useful markers for grading endometrial carcinoma. Cancer 2011. © 2011 American Cancer Society.
RetractedRetracted: Up‐regulation of microRNA‐145 promotes differentiation by repressing OCT4 in human endometrial adenocarcinoma cells
BACKGROUND: MicroRNA‐145 (miR‐145) has been reported to be a tumor‐suppressing agent in several studies. It can repress pluripotency and control human embryonic stem cell differentiation by regulating the core pluripotency factor OCT4. However, it is not known whether miR‐145 can play a role in inducing tumor cell differentiation and repressing growth of tumors. METHODS: Ishikawa cells, the established human endometrial cancer cells, were treated with miR‐145 mimics, inhibitor, or small interfering RNA OCT4. miR‐145 levels were assayed using TaqMan microRNA assays, and the messenger RNA levels of OCT4 and the differentiation marker glycodelin were measured using real‐time polymerase chain reaction. The protein levels of OCT4 and glycodelin were characterized via flow cytometry, western blotting, and immunohistochemistry. In vivo activity was measured in a xenograft mouse model. RESULTS: Up‐regulating miR‐145 reduced the expression of OCT4 and induced the differentiation of Ishikawa cells to closely resemble normal endometrial epithelium both in vitro and in vivo. miR‐145 successfully inhibited tumor growth. We also found that in patients with endometrial carcinoma, miR‐145 and OCT4 were expressed in tissues, and there was a relationship between miR‐145, OCT4, and the degree of tumor cell differentiation. CONCLUSIONS: Our results strongly suggested that miR‐145 is a tumor cell differentiation‐inducing agent in endometrial carcinoma, and that miR‐145 or OCT4 may be useful markers for grading endometrial carcinoma. Cancer 2011. © 2011 American Cancer Society.
- 1 February 2011
- Vol. 46 (2) , 88-93
[Expression changes and clinical significance of annexin V in maternal blood and placenta in patients with preeclampsia].
To evaluate the expression of annexin V in maternal blood and placenta, and to explore the relationship between annexin V and preeclampsia (PE). 120 women with PE who delivered babies in the Second Hospital of Hebei Medical University from December 2007 to December 2009 were chosen as study groups. They were classified into four groups: early-onset mild group (n = 30), early-onset severe group (n = 30), late-onset mild group (n = 30) and late-onset severe group (n = 30). 30 women without perinatal complications who accepted elective term cesarean section were chosen as control group. Western blot and immunohistochemistry were used to detect the expression and localization of annexin V in placenta and maternal blood. Flow cytometry was employed to detect the apoptosis of cytotrophoblast. AnnexinVmRNA level was determined by reverse transcription (RT)PCR. Prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (FiB), international normalized ratio (INR) were detected in each group. (1) The expression of annexin V in placenta and maternal blood were: 0.54 ± 0.12 and 0.62 ± 0.17 in early-onset mild group; 0.47 ± 0.15 and 0.56 ± 0.24 in early-onset severe group; 0.74 ± 0.23 and 1.08 ± 0.32 in late-onset mild group; 0.68 ± 0.28 and 0.72 ± 0.21 in late-onset severe group; 1.73 ± 0.35 and 1.55 ± 0.27 in control group. They were significantly lower in PE groups than in control group (P < 0.05). However, there was no significant difference among PE groups (P > 0.05). (2) The early apoptosis, late apoptosis percentage of trophoblast cells were: 3.21%, 0.86%, in early-onset mild group; 5.32%, 0.72%, in early-onset severe group; 2.43%, 0.63%, in late-onset mild group; 4.28%, 0.48% in late-onset severe group; 1.05%, 0.59%, in control group. Early apoptosis percentage in each group of PE was higher than that in control group (P < 0.05). However, there was no significant difference among PE groups (P > 0.05). (3) The annexin V mRNA levels in placenta were: 25.0 ± 3.0 in early-onset mild group; 24.8 ± 3.0 in early-onset severe group; 25.4 ± 3.9 in late-onset mild group; 25.1 ± 2.7 in late-onset severe group, respectively. All were significantly higher than that in control group (30.6 ± 3.0, P < 0.05), and no significant difference was found among PE groups (P > 0.05). (4) PT, APTT, FiB, INR levels were: (11.3 ± 2.4), (25.6 ± 2.9) s, (4.6 ± 0.9) g/L and 0.9 ± 0.2 in early-onset mild group; (12.1 ± 1.9), (27.2 ± 2.1) s, (5.0 ± 1.0) g/L and 0.9 ± 0.2 in early-onset severe group; (11.7 ± 2.3), (26.5 ± 2.3) s, (5.0 ± 0.7) g/L and 0.8 ± 0.3 in late-onset mild group; (11.4 ± 2.6), (27.3 ± 3.0) s, (4.3 ± 0.8) g/L and 0.8 ± 0.3 in late-onset severe group; (12.4 ± 2.7), (28.0 ± 1.9) s, (5.1 ± 1.2) g/L and 0.9 ± 0.2 in control group. There was no significant difference among PE groups and control group (P > 0.05). The expression changes of annexin V in placenta and maternal blood were observed in patients with PE. This indicated that annexin Vplayed an important role in the pathogenesis and progression of PE by affecting coagulation.
- 1 February 2011
- Vol. 46 (2) , 88-93
[Expression changes and clinical significance of annexin V in maternal blood and placenta in patients with preeclampsia].
To evaluate the expression of annexin V in maternal blood and placenta, and to explore the relationship between annexin V and preeclampsia (PE). 120 women with PE who delivered babies in the Second Hospital of Hebei Medical University from December 2007 to December 2009 were chosen as study groups. They were classified into four groups: early-onset mild group (n = 30), early-onset severe group (n = 30), late-onset mild group (n = 30) and late-onset severe group (n = 30). 30 women without perinatal complications who accepted elective term cesarean section were chosen as control group. Western blot and immunohistochemistry were used to detect the expression and localization of annexin V in placenta and maternal blood. Flow cytometry was employed to detect the apoptosis of cytotrophoblast. AnnexinVmRNA level was determined by reverse transcription (RT)PCR. Prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (FiB), international normalized ratio (INR) were detected in each group. (1) The expression of annexin V in placenta and maternal blood were: 0.54 ± 0.12 and 0.62 ± 0.17 in early-onset mild group; 0.47 ± 0.15 and 0.56 ± 0.24 in early-onset severe group; 0.74 ± 0.23 and 1.08 ± 0.32 in late-onset mild group; 0.68 ± 0.28 and 0.72 ± 0.21 in late-onset severe group; 1.73 ± 0.35 and 1.55 ± 0.27 in control group. They were significantly lower in PE groups than in control group (P < 0.05). However, there was no significant difference among PE groups (P > 0.05). (2) The early apoptosis, late apoptosis percentage of trophoblast cells were: 3.21%, 0.86%, in early-onset mild group; 5.32%, 0.72%, in early-onset severe group; 2.43%, 0.63%, in late-onset mild group; 4.28%, 0.48% in late-onset severe group; 1.05%, 0.59%, in control group. Early apoptosis percentage in each group of PE was higher than that in control group (P < 0.05). However, there was no significant difference among PE groups (P > 0.05). (3) The annexin V mRNA levels in placenta were: 25.0 ± 3.0 in early-onset mild group; 24.8 ± 3.0 in early-onset severe group; 25.4 ± 3.9 in late-onset mild group; 25.1 ± 2.7 in late-onset severe group, respectively. All were significantly higher than that in control group (30.6 ± 3.0, P < 0.05), and no significant difference was found among PE groups (P > 0.05). (4) PT, APTT, FiB, INR levels were: (11.3 ± 2.4), (25.6 ± 2.9) s, (4.6 ± 0.9) g/L and 0.9 ± 0.2 in early-onset mild group; (12.1 ± 1.9), (27.2 ± 2.1) s, (5.0 ± 1.0) g/L and 0.9 ± 0.2 in early-onset severe group; (11.7 ± 2.3), (26.5 ± 2.3) s, (5.0 ± 0.7) g/L and 0.8 ± 0.3 in late-onset mild group; (11.4 ± 2.6), (27.3 ± 3.0) s, (4.3 ± 0.8) g/L and 0.8 ± 0.3 in late-onset severe group; (12.4 ± 2.7), (28.0 ± 1.9) s, (5.1 ± 1.2) g/L and 0.9 ± 0.2 in control group. There was no significant difference among PE groups and control group (P > 0.05). The expression changes of annexin V in placenta and maternal blood were observed in patients with PE. This indicated that annexin Vplayed an important role in the pathogenesis and progression of PE by affecting coagulation.